Home ETF List About

Portfolio Holdings Detail for ISIN IE00B3VWM098
Stock Name / FundiShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc
IssuerBlackrock
Entity holding fund iShares VII Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300Q7FFITMZ2PFZ28
ETF TickerCUS1(GBX) LSE
ETF TickerCUSS(USD) LSE
ETF TickerSXRG(EUR) F
ETF TickerCSUSS.MI(EUR) CXE
ETF TickerCSUSSz(USD) CXE
ETF TickerCUSS.LS(USD) CXE
ETF TickerCSUSS(EUR) ETF Plus
ETF TickerCUS1.L(GBP) LSE
ETF TickerCUSS.L(GBP) LSE

Holdings detail for BBIO

Stock NameBridgeBio Pharma Inc
TickerBBIO(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS10806X1028
LEI54930028YG89VTY2J114

Show aggregate BBIO holdings

News associated with BBIO

How The Parts Add Up: SCHK Headed For $35
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-15 07:18:20
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $70.00 at HC Wainwright
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price target raised by HC Wainwright from $56.00 to $70.00 in a research report report published on Friday,Benzinga reports. The brokerage currently has a buy rating on the stock. A number of other analysts have also recently weighed in on BBIO. Wall Street Zen raised shares of […] - 2025-09-01 03:10:44
BridgeBio Pharma (NASDAQ:BBIO) CFO Sells $2,089,886.76 in Stock
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) CFO Thomas Trimarchi sold 42,237 shares of the stock in a transaction on Thursday, August 21st. The shares were sold at an average price of $49.48, for a total value of $2,089,886.76. Following the sale, the chief financial officer owned 421,081 shares in the company, valued at […] - 2025-08-25 05:07:01
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Sold by Swiss National Bank
Swiss National Bank cut its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 1.0% in the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 238,000 shares of the company’s stock after selling 2,300 shares during the period. Swiss National Bank’s holdings in BridgeBio Pharma were worth […] - 2025-08-17 05:54:57
Sum Up The Parts: JHSC Could Be Worth $46
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-15 09:39:16
Vanguard Group Inc. Cuts Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Vanguard Group Inc. lessened its position in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 1.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,900,145 shares of the company’s stock after selling 177,770 shares during the quarter. Vanguard Group Inc. owned approximately 0.08% of […] - 2025-08-15 06:12:53
BridgeBio Pharma (NASDAQ:BBIO) Raised to “Hold” at Wall Street Zen
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a report issued on Saturday. BBIO has been the topic of several other research reports. Wells Fargo & Company lifted their price target on shares of BridgeBio Pharma from $67.00 […] - 2025-08-11 03:58:51
Brokerages Set BridgeBio Pharma, Inc. (NASDAQ:BBIO) PT at $61.50
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have received an average recommendation of “Buy” from the sixteen brokerages that are presently covering the company, Marketbeat reports. Sixteen analysts have rated the stock with a buy recommendation. The average 1-year price target among brokerages that have issued a report on the stock in […] - 2025-07-30 04:24:53
BridgeBio Pharma (NASDAQ:BBIO) Coverage Initiated at Truist Financial
Equities researchers at Truist Financial began coverage on shares of BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) in a report issued on Monday, MarketBeat.com reports. The brokerage set a “buy” rating and a $66.00 price target on the stock. Truist Financial’s price target would indicate a potential upside of 44.20% from the company’s current price. […] - 2025-07-23 05:10:52
BridgeBio Pharma (NASDAQ:BBIO) Coverage Initiated at Jefferies Financial Group
Equities research analysts at Jefferies Financial Group initiated coverage on shares of BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) in a note issued to investors on Monday, Marketbeat reports. The brokerage set a “buy” rating and a $70.00 price target on the stock. Jefferies Financial Group’s price target points to a potential upside of 49.03% […] - 2025-07-16 02:50:48
BridgeBio Pharma (NASDAQ:BBIO) Price Target Raised to $68.00 at Piper Sandler
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its price objective boosted by Piper Sandler from $63.00 to $68.00 in a research note published on Monday,Benzinga reports. The firm currently has an overweight rating on the stock. Several other equities research analysts have also recently weighed in on BBIO. Bank of America increased their price objective […] - 2025-07-15 06:21:07
BridgeBio Pharma (NASDAQ:BBIO) Raised to “Outperform” at Oppenheimer
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) was upgraded by stock analysts at Oppenheimer from a “market perform” rating to an “outperform” rating in a note issued to investors on Wednesday, Marketbeat Ratings reports. The brokerage presently has a $60.00 price objective on the stock. Oppenheimer’s price target would suggest a potential upside of 29.67% […] - 2025-07-11 02:20:48
Principal Financial Group Inc. Has $39.70 Million Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Principal Financial Group Inc. lifted its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 9.3% during the first quarter, HoldingsChannel reports. The fund owned 1,148,292 shares of the company’s stock after purchasing an additional 98,153 shares during the quarter. Principal Financial Group Inc.’s holdings in BridgeBio Pharma were worth $39,696,000 as of its […] - 2025-07-07 05:54:48
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Major Shareholder Sells $154,000,000.00 in Stock
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) major shareholder Global Investors Lp Viking sold 3,500,000 shares of the stock in a transaction on Friday, June 27th. The stock was sold at an average price of $44.00, for a total value of $154,000,000.00. Following the completion of the sale, the insider owned 18,555,375 shares in […] - 2025-07-03 06:00:52
BridgeBio Pharma (NASDAQ:BBIO) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price objective hoisted by equities researchers at Wells Fargo & Company from $67.00 to $76.00 in a report issued on Monday,Benzinga reports. The firm presently has an “overweight” rating on the stock. Wells Fargo & Company‘s target price indicates a potential upside of 77.65% from the […] - 2025-07-02 02:32:50
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Given Average Recommendation of “Moderate Buy” by Brokerages
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have earned a consensus rating of “Moderate Buy” from the thirteen analysts that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and twelve have given a buy recommendation to the company. The average 12-month […] - 2025-06-30 02:46:48
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Director Frank Mccormick Sells 100,000 Shares
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) Director Frank Mccormick sold 100,000 shares of BridgeBio Pharma stock in a transaction on Tuesday, June 24th. The shares were sold at an average price of $44.23, for a total value of $4,423,000.00. Following the completion of the transaction, the director now owns 879,979 shares in the […] - 2025-06-29 05:16:56
BridgeBio Pharma (NASDAQ:BBIO) Given New $54.00 Price Target at Bank of America
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price objective raised by equities researchers at Bank of America from $50.00 to $54.00 in a research report issued on Wednesday,Benzinga reports. The firm presently has a “buy” rating on the stock. Bank of America‘s target price would suggest a potential upside of 19.68% from the […] - 2025-06-27 02:28:43
BridgeBio Pharma (NASDAQ:BBIO) Given New $56.00 Price Target at HC Wainwright
BridgeBio Pharma (NASDAQ:BBIO – Get Free Report) had its price target lifted by analysts at HC Wainwright from $53.00 to $56.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has a “buy” rating on the stock. HC Wainwright’s price objective suggests a potential upside of 39.69% from the company’s previous […] - 2025-06-11 02:44:48
California State Teachers Retirement System Raises Stock Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)
California State Teachers Retirement System lifted its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 6.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 115,655 shares of the company’s stock after buying an additional 7,388 shares during the quarter. […] - 2025-06-05 06:18:53
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Mackenzie Financial Corp
Mackenzie Financial Corp increased its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 6.6% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 9,505 shares of the company’s stock after purchasing an additional 592 shares during the […] - 2025-06-05 05:26:59
Better High-Yield Dividend Stock to Buy Now: Pfizer vs. Prologis
Investors looking for sources of passive income to fuel their retirement dreams face a dilemma. Should you chase high yields from slow-growing businesses or invest in lower-yield providers with more predictable cash flows? - 2025-06-05 04:34:00
Dimensional Fund Advisors LP Reduces Stock Holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Dimensional Fund Advisors LP cut its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 1.7% during the 4th quarter, Holdings Channel reports. The fund owned 61,665 shares of the company’s stock after selling 1,036 shares during the period. Dimensional Fund Advisors LP’s holdings in BridgeBio Pharma were worth $1,692,000 as of its most […] - 2025-05-15 04:32:47
Analysts Set BridgeBio Pharma, Inc. (NASDAQ:BBIO) Target Price at $57.09
Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) have been given a consensus recommendation of “Moderate Buy” by the twelve ratings firms that are presently covering the firm, Marketbeat Ratings reports. One research analyst has rated the stock with a hold rating and eleven have issued a buy rating on the company. The […] - 2025-05-14 02:34:53
Envestnet Asset Management Inc. Reduces Position in BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Envestnet Asset Management Inc. reduced its holdings in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 18.6% during the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 12,926 shares of the company’s stock after selling 2,949 shares during the period. Envestnet Asset Management Inc.’s holdings in BridgeBio Pharma were worth $355,000 at the end of […] - 2025-05-06 04:22:45
BridgeBio Pharma (NASDAQ:BBIO) Reaches New 1-Year High After Better-Than-Expected Earnings
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) shares reached a new 52-week high during trading on Wednesday following a better than expected earnings announcement. The company traded as high as $39.54 and last traded at $38.48, with a volume of 2185851 shares. The stock had previously closed at $36.42. The company reported ($0.88) earnings […] - 2025-05-02 02:09:05
BridgeBio Pharma Target of Unusually High Options Trading (NASDAQ:BBIO)
BridgeBio Pharma, Inc. (NASDAQ:BBIO – Get Free Report) saw some unusual options trading activity on Monday. Stock investors purchased 5,930 put options on the company. This is an increase of 67% compared to the typical volume of 3,542 put options. Wall Street Analysts Forecast Growth A number of equities research analysts have commented on the […] - 2025-04-30 04:24:51
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Acquired by Legal & General Group Plc
Legal & General Group Plc increased its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 2.8% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 134,038 shares of the company’s stock after acquiring an additional 3,706 shares […] - 2025-04-23 05:21:00
BridgeBio Pharma, Inc. (NASDAQ:BBIO) Shares Sold by Prudential Financial Inc.
Prudential Financial Inc. reduced its stake in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 24.4% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,429 shares of the company’s stock after selling 3,360 shares during the period. Prudential Financial Inc.’s holdings in BridgeBio […] - 2025-04-11 05:02:57
Vanguard Group Inc. Buys 879,059 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO)
Vanguard Group Inc. raised its stake in BridgeBio Pharma, Inc. (NASDAQ:BBIO – Free Report) by 6.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 15,077,915 shares of the company’s stock after purchasing an additional 879,059 shares during the period. Vanguard […] - 2025-04-03 04:37:03

iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc BBIO holdings

DateNumber of BBIO Shares HeldBase Market Value of BBIO SharesLocal Market Value of BBIO SharesChange in BBIO Shares HeldChange in BBIO Base ValueCurrent Price per BBIO Share HeldPrevious Price per BBIO Share Held
2025-09-26 (Friday)38,812USD 1,942,541USD 1,942,541
2025-09-25 (Thursday)38,812USD 1,901,788BBIO holding decreased by -64040USD 1,901,7880USD -64,040 USD 49 USD 50.65
2025-09-24 (Wednesday)38,812USD 1,965,828USD 1,965,828
2025-09-17 (Wednesday)38,560USD 1,973,501BBIO holding decreased by -11953USD 1,973,5010USD -11,953 USD 51.18 USD 51.49
2025-09-16 (Tuesday)38,560USD 1,985,454USD 1,985,454
2025-09-12 (Friday)38,308USD 1,961,753USD 1,961,753
2025-09-11 (Thursday)38,308USD 2,015,001USD 2,015,001
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of BBIO by Blackrock for IE00B3VWM098

Show aggregate share trades of BBIO

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-08-21SELL-83 50.230* 34.61 Profit of 2,873 on sale
2025-07-31BUY249 47.270* 34.45
2025-06-30SELL-166 43.180* 33.05 Profit of 5,486 on sale
2025-06-25SELL-83 44.380* 32.80 Profit of 2,723 on sale
2025-06-20SELL-166 41.730* 32.59 Profit of 5,410 on sale
2025-05-30BUY2,758 34.250* 31.85
2025-05-23BUY73 33.340* 31.80
2025-05-19SELL-73 33.690* 31.75 Profit of 2,318 on sale
2025-05-15SELL-219 33.740* 31.71 Profit of 6,945 on sale
2025-05-12SELL-73 35.680* 31.64 Profit of 2,310 on sale
2025-05-09SELL-73 34.170* 31.62 Profit of 2,308 on sale
2025-04-30SELL-73 38.360* 31.23 Profit of 2,280 on sale
2025-04-24SELL-146 35.960* 31.04 Profit of 4,531 on sale
2025-04-17SELL-73 33.870* 30.87 Profit of 2,254 on sale
2025-04-15SELL-219 34.240* 30.80 Profit of 6,746 on sale
2025-04-14SELL-219 34.850* 30.76 Profit of 6,736 on sale
2025-04-09SELL-296 32.880* 30.68 Profit of 9,082 on sale
2025-04-07SELL-518 30.670* 30.69 Profit of 15,896 on sale
2025-04-04SELL-740 31.370* 30.68 Profit of 22,703 on sale
2025-03-31BUY74 34.570* 30.56
2025-03-19SELL-148 33.750* 30.02 Profit of 4,443 on sale
2025-03-14SELL-444 32.970* 29.91 Profit of 13,279 on sale
2025-03-13SELL-148 32.310* 29.87 Profit of 4,421 on sale
2025-03-12SELL-2,516 32.590* 29.83 Profit of 75,059 on sale
2025-03-07SELL-148 31.570* 29.74 Profit of 4,402 on sale
2025-03-06SELL-222 32.230* 29.71 Profit of 6,595 on sale
2025-03-03SELL-74 33.010* 29.51 Profit of 2,183 on sale
2025-02-28BUY9,779 34.900* 29.42
2025-02-26SELL-47 33.450* 29.27 Profit of 1,376 on sale
2025-02-25SELL-141 34.350* 29.18 Profit of 4,114 on sale
2025-02-18BUY235 35.490* 28.51
2025-02-13BUY47 31.560* 28.19
2025-02-12BUY47 31.950* 28.11
2025-02-11BUY141 31.120* 28.05
2025-02-06BUY423 32.700* 27.78
2025-01-27BUY47 36.670* 26.29
2024-12-30BUY235 27.320* 25.54
2024-12-06BUY188 28.790* 25.18
2024-12-05BUY47 26.660* 25.13
2024-12-04BUY235 27.100* 25.06
2024-11-29BUY235 27.090* 24.85
2024-11-27BUY184 27.490* 24.62
2024-11-26BUY46 26.440* 24.54
2024-11-21BUY230 23.240* 24.53
2024-11-20BUY138 23.040* 24.61
2024-11-18BUY552 22.350* 24.88
2024-11-12BUY368 24.620* 24.90
2024-11-08BUY230 27.090* 24.74
2024-11-07BUY690 25.880* 24.65
2024-11-06BUY92 25.610* 24.58
2024-10-31BUY46 23.410* 24.41
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of BBIO

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19356,0957,744678,15552.5%
2025-09-18261,504130637,84641.0%
2025-09-17334,7725480,57069.7%
2025-09-161,357,45318,5091,506,01190.1%
2025-09-15368,036160570,02864.6%
2025-09-12529,781105881,47760.1%
2025-09-11223,4790539,51841.4%
2025-09-10442,5835754,80058.6%
2025-09-09595,671419896,06666.5%
2025-09-08594,2206,754924,64464.3%
2025-09-05738,70433,5111,278,64957.8%
2025-09-04401,29528,014663,39360.5%
2025-09-03560,60920,6291,223,39745.8%
2025-09-02463,65741,7911,121,26941.4%
2025-08-291,323,234439,7471,802,27173.4%
2025-08-28760,1626,3501,209,35162.9%
2025-08-27848,64511,0341,399,82460.6%
2025-08-26320,263175800,50940.0%
2025-08-25255,972558695,15636.8%
2025-08-22216,24411,104516,38741.9%
2025-08-21150,2330456,53432.9%
2025-08-20351,9861,187776,88145.3%
2025-08-19262,2421,055685,16738.3%
2025-08-18732,294233,0841,316,99255.6%
2025-08-15300,2908,510664,74745.2%
2025-08-14352,3000731,29048.2%
2025-08-13621,1841,051969,79264.1%
2025-08-12492,72842,100791,91862.2%
2025-08-11379,9683,205763,58249.8%
2025-08-08467,277204775,46160.3%
2025-08-07571,5457,0951,074,64553.2%
2025-08-063,823,10952,4265,661,91367.5%
2025-08-051,384,6322111,958,93770.7%
2025-08-04359,9610855,64342.1%
2025-08-01377,5770796,89247.4%
2025-07-31363,917889946,80338.4%
2025-07-30316,215797675,92946.8%
2025-07-29135,1952,991402,97033.5%
2025-07-28224,253300807,07627.8%
2025-07-25236,2520539,15343.8%
2025-07-24211,044108664,61131.8%
2025-07-23240,0101,150906,17626.5%
2025-07-22418,8211,614778,68553.8%
2025-07-21370,15250801,28546.2%
2025-07-18403,386312850,69247.4%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.